• 76543 Citations
  • 135 h-Index
1989 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Letter
2019

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

Strati, P., Garcia-Manero, G., Zhao, C., Kadia, T., Borthakur, G., Konopleva, M., Daver, N., DiNardo, C. D., Short, N. J., Yilmaz, M., Naqvi, K., Alvarado, Y., Pierce, S. A., Cortes, J., Bueso-Ramos, C., Kantarjian, H. & Ravandi, F., Jul 2019, In : American Journal of Hematology. 94, 7, p. E188-E190

Research output: Contribution to journalLetter

Open Access

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series

Rafei, H., Jabbour, E. J., Kantarjian, H., Sinicrope, K. D., Kamiya-Matsuoka, C., Mehta, R. S., Daver, N. G., Kadia, T. M., Naqvi, K., Cortes, J. & Konopleva, M., Nov 10 2019, In : Leukemia and Lymphoma. 60, 13, p. 3292-3295 4 p.

Research output: Contribution to journalLetter

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia

Abbas, H. A., Ravandi, F., Loghavi, S., Patel, K. P., Borthakur, G., Kadia, T. M., Jabbour, E., Takahashi, K., Cortes, J., Issa, G. C., Konopleva, M., Kantarjian, H. M. & Short, N. J., Jun 2019, In : American Journal of Hematology. 94, 6, p. E158-E160

Research output: Contribution to journalLetter

Open Access
7 Scopus citations

Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia

Gong, Z., Xu, M. L., Chen, M., Cui, W., Kantarjian, H. M., Cortes, J. E., Zhou, T., Tang, G., Wang, W., Medeiros, L. J. & Hu, S., Oct 1 2019, In : American Journal of Hematology. 94, 10, p. E256-E259

Research output: Contribution to journalLetter

Open Access

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

Bixby, D., Noppeney, R., Lin, T. L., Cortes, J., Krauter, J., Yee, K., Medeiros, B. C., Krämer, A., Assouline, S., Fiedler, W., Dimier, N., Simmons, B. P., Riehl, T. & Colburn, D., May 2019, In : British Journal of Haematology. 185, 3, p. 595-598 4 p.

Research output: Contribution to journalLetter

2 Scopus citations

Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia

Alfayez, M., Richard-Carpentier, G., Jabbour, E., Vishnu, P., Naqvi, K., Sasaki, K., Cortes, J. & Pemmaraju, N., Nov 1 2019, In : British Journal of Haematology. 187, 4, p. 543-545 3 p.

Research output: Contribution to journalLetter

Open Access
2 Scopus citations
2018

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

Boddu, P., Jorgensen, J., Kantarjian, H., Borthakur, G., Kadia, T., Daver, N., Alvarado, Y., Pemmaraju, N., Bose, P., Naqvi, K., Yilmaz, M., Pierce, S., Brandt, M., DiNardo, C. D., Jabbour, E. J., Konopleva, M., Garcia-Manero, G., Cortes, J. & Ravandi, F., Jan 2018, In : Leukemia. 32, 1, p. 241-244 4 p.

Research output: Contribution to journalLetter

12 Scopus citations

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia

Short, N. J., Kantarjian, H., Jabbour, E., Cortes, J. E., Thomas, D. A., Rytting, M. E., Daver, N., Alvarado, Y., Konopleva, M., Kebriaei, P., Wierda, W. G., DiNardo, C. D., Bivins, C., McCue, D., Richie, M. A. & Ravandi, F., Aug 2018, In : British Journal of Haematology. 182, 3, p. 442-444 3 p.

Research output: Contribution to journalLetter

3 Scopus citations

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Ottmann, O., Saglio, G., Apperley, J. F., Arthur, C., Bullorsky, E., Charbonnier, A., Dipersio, J. F., Kantarjian, H., Khoury, H. J., Kim, D. W., Healey, D., Strauss, L. & Cortes, J. E., Sep 1 2018, In : Blood Cancer Journal. 8, 9, 88.

Research output: Contribution to journalLetter

Open Access
1 Scopus citations

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

Boddu, P., Kantarjian, H., Ravandi, F., Garcia-Manero, G., Borthakur, G., Andreeff, M., Jabbour, E. J., Benton, C. B., DiNardo, C. D., Konopleva, M., Daver, N., Patel, K., Takahashi, K., Kanagal-Shamanna, R., Cortes, J. & Kadia, T., Sep 2 2018, In : Leukemia and Lymphoma. 59, 9, p. 2238-2241 4 p.

Research output: Contribution to journalLetter

3 Scopus citations

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., Vey, N., Strickland, S. A., Schiller, G. J., Jabbour, E., Pigneux, A., Horst, H. A., Récher, C., Klimek, V. M., Cortes, J. E., Carella, A. M., Egyed, M., Krug, U., Fox, J. A., Craig, A. R., Ward, R. & 4 others, Smith, J. A., Acton, G., Kantarjian, H. M. & Stuart, R. K., Oct 31 2018, In : Haematologica. 103, 11, p. e514-e518

Research output: Contribution to journalLetter

Open Access
3 Scopus citations

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia

Abaza, Y., Cortes, J., Ravandi, F., Kadia, T., Garcia-Manero, G., Pemmaraju, N., Shetty, A., Pierce, S., Qiao, W., Kantarjian, H. M. & Borthakur, G., Nov 2018, In : American Journal of Hematology. 93, 11, p. E357-E360

Research output: Contribution to journalLetter

Open Access

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

Boddu, P., Kantarjian, H., Garcia-Manero, G., Ravandi, F., Jabbour, E., Borthakur, G., Daver, N., Pemmaraju, N., Pierce, S., Cortes, J. & Kadia, T. M., Aug 23 2018, In : Leukemia and Lymphoma. 59, 4, p. 1012-1015 4 p.

Research output: Contribution to journalLetter

1 Scopus citations
2017

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia

Gong, Z., Medeiros, L. J., Cortes, J. E., Zheng, L., Khoury, J. D., Wang, W., Tang, G., Loghavi, S., Luthra, R., Yang, W., Kantarjian, H. M. & Hu, S., Jan 1 2017, In : Blood Cancer Journal. 7, 7, e583.

Research output: Contribution to journalLetter

Open Access
9 Scopus citations

Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens

Jain, P., Kantarjian, H., Jain, N., Short, N. J., Yin, C. C., Kanagal-Shamanna, R., Khoury, J., Konopleva, M., Sasaki, K., Kadia, T. M., Garris, R., Pierce, S., Estrov, Z., Wierda, W., Cortes, J., O'Brien, S., Ravandi, F. & Jabbour, E., Oct 2017, In : American Journal of Hematology. 92, 10, p. E595-E597

Research output: Contribution to journalLetter

5 Scopus citations

Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias—(De novo and blast phase CML)

Jain, P., Kantarjian, H., Jabbour, E., Kanagal-Shamanna, R., Patel, K., Pierce, S., Garcia-Manero, G., Borthakur, G., Ravandi, F., O'Brien, S. & Cortes, J., Jan 1 2017, In : American Journal of Hematology. 92, 1, p. E3-E4

Research output: Contribution to journalLetter

6 Scopus citations

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia

Chen, Z., Medeiros, L. J., Kantajian, H. M., Zheng, L., Gong, Z., Patel, K. P., Xiong, H., Wang, W., Cortes, J. E. & Hu, S., Feb 3 2017, In : Blood Cancer Journal. 7, 2, e521.

Research output: Contribution to journalLetter

Open Access
4 Scopus citations

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Kongtim, P., Adekola, K., Milton, D. R., Ramlal, R., Jimenez, A., Chen, J., Rondon, G., Ahmed, S., Kebriaei, P., Betul, O., Hosing, C. M., Popat, U., Khouri, I., Jabbour, E., Cortes, J. E., Kantarjian, H. M., Champlin, R. E. & Ciurea, S. O., Jul 1 2017, In : Leukemia. 31, 7, p. 1654-1657 4 p.

Research output: Contribution to journalLetter

4 Scopus citations

Influence of IDH on FLT3-ITD status in newly diagnosed AML

Boddu, P., Takahashi, K., Pemmaraju, N., Daver, N., Benton, C. B., Pierce, S., Konopleva, M., Ravandi, F., Cortes, J., Kantarjian, H. & DiNardo, C. D., Nov 1 2017, In : Leukemia. 31, 11, p. 2526-2529 4 p.

Research output: Contribution to journalLetter

5 Scopus citations

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia

Montalban-Bravo, G., Benton, C. B., Wang, S. A., Ravandi, F., Kadia, T., Cortes, J., Daver, N., Takahashi, K., Dinardo, C., Jabbour, E., Borthakur, G., Konopleva, M., Pierce, S., Bueso-Ramos, C., Patel, K., Kornblau, S., Kantarjian, H., Young, K. H., Garcia-Manero, G. & Andreeff, M., May 4 2017, In : Blood. 129, 18, p. 2584-2587 4 p.

Research output: Contribution to journalLetter

Open Access
10 Scopus citations

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

Short, N. J., Kantarjian, H. M., Ko, H., Khoury, J. D., Ravandi, F., Thomas, D. A., Garcia-Manero, G., Khouri, M., Cortes, J. E., Wierda, W. G., Verstovsek, S., Estrov, Z., Ferrajoli, A., Thompson, P. A., Pierce, S., O'Brien, S. M. & Jabbour, E., Jun 2017, In : American Journal of Hematology. 92, 6, p. E114-E117

Research output: Contribution to journalLetter

6 Scopus citations

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

Maiti, A., Cortes, J. E., Brown, Y. D. & Kantarjian, H. M., Mar 4 2017, In : Leukemia and Lymphoma. 58, 3, p. 722-725 4 p.

Research output: Contribution to journalLetter

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

Maiti, A., Cortes, J., Ferrajoli, A., Estrov, Z., Borthakur, G., Garcia-Manero, G., Jabbour, E., Ravandi, F., O’Brien, S. & Kantarjian, H., Sep 2 2017, In : Leukemia and Lymphoma. 58, 9, p. 2240-2242 3 p.

Research output: Contribution to journalLetter

3 Scopus citations

Reply to K.R. Hoffman

Cortes, J. E. & Hochhaus, A., Feb 10 2017, In : Journal of Clinical Oncology. 35, 5, p. 567-568 2 p.

Research output: Contribution to journalLetter

1 Scopus citations
2016

CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count

Sanford, D., Garcia-Manero, G., Jorgensen, J., Konoplev, S., Pierce, S., Cortes, J., Kantarjian, H. & Ravandi, F., Aug 2 2016, In : Leukemia and Lymphoma. 57, 8, p. 1965-1968 4 p.

Research output: Contribution to journalLetter

3 Scopus citations

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Chen, Z., Wang, W., Cortes, J. E., Liu, E., Miranda, R. N., Zhao, C., Yuan, J., Lu, X., Yang, W., Ameri, M. D., Kantarjian, H. M., Medeiros, L. J. & Hu, S., May 6 2016, In : Blood Cancer Journal. 6, e418.

Research output: Contribution to journalLetter

Open Access
2 Scopus citations

Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Chen, Z., Cortes, J. E., Jorgensen, J. L., Wang, W., Yin, C. C., You, M. J., Jabbour, E., Kantarjian, H. M., Medeiros, L. J. & Hu, S., Jul 1 2016, In : Leukemia. 30, 7, p. 1606-1609 4 p.

Research output: Contribution to journalLetter

13 Scopus citations

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis

Sasaki, K., Kantarjian, H., Jabbour, E., Ravandi, F., Takahashi, K., Konopleva, M., Borthakur, G., Garcia-Manero, G., Wierda, W., Daver, N., Jain, P., Satta, T., Pierce, S., Rios, M. B. & Cortes, J. E., Jul 31 2016, In : Haematologica. 101, 8, p. e324-e327

Research output: Contribution to journalLetter

Open Access
2 Scopus citations

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

Le Coutre, P. D., Hughes, T. P., Mahon, F. X., Kim, D. W., Steegmann, J. L., Shah, N. P., Gooden, K., Wallis, N. & Cortes, J. E., Jul 1 2016, In : Leukemia. 30, 7, p. 1593-1596 4 p.

Research output: Contribution to journalLetter

Open Access
8 Scopus citations

Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experience

Masarova, L., Cherry, M., Newberry, K. J., Estrov, Z., Cortes, J. E., Kantarjian, H. M. & Verstovsek, S., Jan 2 2016, In : Leukemia and Lymphoma. 57, 1, p. 237-239 3 p.

Research output: Contribution to journalLetter

14 Scopus citations
2015

Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm

Chen, Z., Wang, W., Verstovsek, S., Cortes, J. E., Medeiros, L. J. & Hu, S., Jan 1 2015, In : International Journal of Laboratory Hematology. 37, 6, p. e150-e152

Research output: Contribution to journalLetter

2 Scopus citations

Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

Wang, W., Cortes, J. E., Lin, P., Khoury, J. D., Ai, D., Tang, Z., Tang, G., Jorgensen, J. L., Medeiros, L. J. & Hu, S., Nov 1 2015, In : Leukemia. 29, 11, p. 2263-2266 4 p.

Research output: Contribution to journalLetter

18 Scopus citations

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1

Loghavi, S., Pemmaraju, N., Kanagal-Shamanna, R., Mehrotra, M., Medeiros, L. J., Luthra, R., Lin, P., Huh, Y., Kantarjian, H. M., Cortes, J. E., Verstovsek, S. & Patel, K. P., Jan 1 2015, In : Blood. 125, 21, p. 3360-3363 4 p.

Research output: Contribution to journalLetter

Open Access
14 Scopus citations

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

Sanford, D., Kantarjtan, H., Skinner, J., Jabbour, E. & Cortes, J., Jan 1 2015, In : Haematologica. 100, 12, p. e494-e495

Research output: Contribution to journalLetter

Open Access
12 Scopus citations

Prediction of response and survival in patients with chronicphase chronic myeloid leukemia treated with omacetaxine mepesuccinate: Logistic regression and landmark analyses

Wetzler, M., Kantarjian, H. M., Nicolini, F. E., Lipton, J. H., Akard, L., Baccarani, M., Khoury, H. J., Li, E., Munteanu, M. & Cortes, J., Dec 11 2015, In : Blood Cancer Journal. 5, 12, e376.

Research output: Contribution to journalLetter

Open Access
1 Scopus citations

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

Kadia, T., Kantarjian, H., Garcia-Manero, G., Borthakur, G., Wang, X., Patel, K., Jabbour, E., Brandt, M., Daver, N., Pemmaraju, N., Pierce, S., Cortes, J. & Ravandi, F., Aug 1 2015, In : British Journal of Haematology. 170, 4, p. 590-593 4 p.

Research output: Contribution to journalLetter

9 Scopus citations
2014

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations

Benton, C. B., Ravandi, F., Andreeff, M., Kadia, T., Ruvolo, V., Qiu, P., Wheeler, D. A., Garcia-Manero, G., Cortes, J., Kantarjian, H. M. & Konopleva, M., Jun 2014, In : Leukemia and Lymphoma. 55, 6, p. 1431-1434 4 p.

Research output: Contribution to journalLetter

6 Scopus citations
11 Scopus citations

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

Ravandi, F., Arana Yi, C., Cortes, J. E., Levis, M., Faderl, S., Garcia-Manero, G., Jabbour, E., Konopleva, M., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S., Brandt, M., Pratz, K., Luthra, R., Andreeff, M. & Kantarjian, H., Jul 2014, In : Leukemia. 28, 7, p. 1543-1545 3 p.

Research output: Contribution to journalLetter

48 Scopus citations

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

Dinardo, C. D., Patel, K. P., Garcia-Manero, G., Luthra, R., Pierce, S., Borthakur, G., Jabbour, E., Kadia, T., Pemmaraju, N., Konopleva, M., Faderl, S., Cortes, J., Kantarjian, H. M. & Ravandi, F., Aug 2014, In : Leukemia and Lymphoma. 55, 8, p. 1925-1929 5 p.

Research output: Contribution to journalLetter

37 Scopus citations

Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy

Dinardo, C. D., Daver, N., Jain, N., Pemmaraju, N., Bueso-Ramos, C., Yin, C. C., Pierce, S., Jabbour, E., Cortes, J. E., Kantarjian, H. M., Garcia-Manero, G. & Verstovsek, S., Apr 2014, In : Leukemia. 28, 4, p. 958-961 4 p.

Research output: Contribution to journalLetter

33 Scopus citations

Single-agent liposomal all-trans-retinoic acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data

Jain, P., Kantarjian, H., Estey, E., Pierce, S., Cortes, J., Lopez-Berestein, G. & Ravandi, F., Feb 1 2014, In : Clinical Lymphoma, Myeloma and Leukemia. 14, 1, p. e47-e49

Research output: Contribution to journalLetter

Open Access
6 Scopus citations

The authors reply

Cortes, J. E., Talpaz, M. & Kantarjian, H., Feb 12 2014, In : New England Journal of Medicine. 370, 6, 1 p.

Research output: Contribution to journalLetter

11 Scopus citations

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

Jain, P., Kantarjian, H., Ravandi, F., Thomas, D., O'Brien, S., Kadia, T., Burger, J., Borthakur, G., Daver, N., Jabbour, E., Konopleva, M., Cortes, J., Pemmaraju, N., Kelly, M. A., Cardenas-Turanzas, M., Garris, R. & Faderl, S., Apr 2014, In : Leukemia. 28, 4, p. 973-975 3 p.

Research output: Contribution to journalLetter

27 Scopus citations
2013

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia

Ostronoff, F., Othus, M., Kantarjian, H. M., Meshinchi, S., Ravandi, F., Hendrie, P. C., Faderl, S., Becker, P. S., Cortes, J. E., Pagel, J. M., Petersdorf, S. H., Godwin, J. E., Willman, C. L., Pierce, S. A., List, A. F., Sandhu, R. K., Walter, R. B., Stirewalt, D. L., Appelbaum, F. R. & Estey, E. H., Oct 1 2013, In : British Journal of Haematology. 163, 1, p. 130-132 3 p.

Research output: Contribution to journalLetter

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts

Jain, P., Guillermo Romo, C., Khoury, H. J., Kantarjian, H. & Cortes, J., Nov 1 2013, In : Haematologica. 98, 11, p. e141-e142

Research output: Contribution to journalLetter

Open Access
3 Scopus citations

Double-hit of FLT3 gene in a fatal case of acute myemonocytic leukaemia

Lu, G., Schulz, R. A., Bueso-Ramos, C. E., Cortes, J. E., Wang, X. I., Medeiros, L. J. & Yin, C. C., Sep 1 2013, In : Journal of Clinical Pathology. 66, 9, p. 826-829 4 p.

Research output: Contribution to journalLetter

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

Takahashi, K., Jabbour, E., Wang, X., Luthra, R., Bueso-Ramos, C., Patel, K., Pierce, S., Yang, H., Wei, Y., Daver, N., Faderl, S., Ravandi, F., Estrov, Z., Cortes, J., Kantarjian, H. & Garcia-Manero, G., Oct 1 2013, In : Leukemia. 27, 10, p. 2081-2083 3 p.

Research output: Contribution to journalLetter

Open Access
26 Scopus citations

Is there a standard induction regimen for patients with AML?

Ravandi, F., Cortes, J. & Kantarjian, H., Jun 1 2013, In : The Lancet Oncology. 14, 7, p. 565-566 2 p.

Research output: Contribution to journalLetter

1 Scopus citations

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

Nicolini, F. E., Khoury, H. J., Akard, L., Rea, D., Kantarjian, H., Baccarani, M., Leonoudakis, J., Craig, A., Benichou, A. C. & Cortes, J., Jul 1 2013, In : Haematologica. 98, 7, p. e78-e79

Research output: Contribution to journalLetter

Open Access
16 Scopus citations